


PHARMACEUTICAL 2023

Evofem Biosciences Inc. Rank 411 of 446







Evofem Biosciences Inc. Rank 411 of 446

The relative strengths and weaknesses of Evofem Biosciences Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Evofem Biosciences Inc. compared to the market average is the variable Other Compr. Net Income, increasing the Economic Capital Ratio by 37% points. The greatest weakness of Evofem Biosciences Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 259% points.

The company's Economic Capital Ratio, given in the ranking table, is -291%, being 335% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	12,699
Cost of Goods Sold	4,415
Intangible Assets	0
Liabilities, Current	93,830
Liabilities, Non-Current	3,133
Other Assets	8,524
Other Compr. Net Income	44,438
Other Expenses	43,995
Other Liabilities	0
Other Net Income	7,470
Other Revenues	16,837
Property and Equipment	3,940
Research and Development	25,032
Selling, General and Administrative Expense	27,563

Output Variable	Value in 1000 USD
Assets	25,163
Liabilities	96,963
Expenses	101,005
Revenues	16,837
Stockholders Equity	-71,800
Net Income	-76,698
Comprehensive Net Income	-54,479
Economic Capital Ratio	-291%

